- CRISPR nickase is identified as the “most important component” in a recent paper yet is mentioned only four times, underscoring a broader concern that gene-editing literature may systematically under-report key reagents.  
- Feasibility of photosynthetic human power was modeled: ~50 m² of optimally oriented leaf area per person is required, far below earlier “square-kilometer” claims; participants proposed engineering higher-efficiency chloroplasts or reflector-based constant daylight to close the gap.  
- Creating a zygote “from scratch” is currently blocked by genome-synthesis costs of “many tens of millions of dollars,” but the 2016 Nature paper on in-vitro reconstitution of the entire mouse female germ line was cited as a path to an “embryo fountain” enabling large-scale embryo selection.  
- Myostatin inhibition for muscle enhancement faces tendon-strength trade-offs; solutions discussed include α-myosin tissue-specific promoters, inducible expression systems, and follistatin as an alternative target for controlled hypertrophy.  
- The first documented self-experiment with CRISPR in a human (http://www.ifyoudontknownowyaknow.com/2017/10/the-first-human-to-attempt-crispr-gene.html) was shared, prompting debate on public reactions to “designer babies” and the ethics of germline editing.  
- Personalized therapeutics could be produced at consumer-product cost if low-risk interventions bypass traditional clinical trials, an argument likened to buying custom shoes rather than pharmaceuticals.  
- DNA data storage was framed as both archival medium and programmable substrate via two articles: “Making DNA Data Storage a Reality” (The Scientist) and “The Next Software Revolution Will Rewrite Life as We Know It” (Scout.ai).  
- A PLOS ONE paper (10.1371/journal.pone.0069805) showing intact dietary genes in human blood sparked discussion of “gene therapy food” as a non-invasive nucleic-acid delivery vector.  
- Follistatin, membrane-bound inhibitors, and tissue-specific promoters were confirmed as tools capable of targeting ~200 differentiated human cell types, suggesting near-comprehensive precision for future somatic gene editing.